We recognize that the profound impact of mammalian-derived biotherapeutics hinges on their structural and functional integrity. Rigorous analytical characterization is not merely a regulatory requirement; it is the cornerstone of developing safe, effective, and consistent therapies. As a leader in integrated CDMO Solutions, we provide comprehensive Mammalian Protein CDMO Solutions, with our specialized Analytical Services forming a critical pillar.
Overview of Mammalian Protein Analytical Characterization
Mammalian proteins, including monoclonal antibodies, enzymes, growth factors, and complex fusion proteins, exhibit intricate post-translational modifications (PTMs) such as glycosylation, phosphorylation, and oxidation. These modifications profoundly influence critical quality attributes (CQAs) like stability, solubility, biological activity, pharmacokinetics, and immunogenicity. Comprehensive analytical characterization is therefore non-negotiable. It involves a sophisticated suite of orthogonal techniques to elucidate primary, secondary, tertiary, and quaternary structure, quantify purity and impurities, assess potency, and monitor stability. This deep molecular understanding is essential for establishing robust manufacturing processes, ensuring batch-to-batch consistency, and meeting stringent regulatory expectations. Our analytical services are designed specifically to navigate this complexity.
Our Comprehensive Mammalian Protein Analytical Services
Leveraging state-of-the-art instrumentation and deep scientific expertise, we offer a complete spectrum of analytical services tailored to mammalian protein therapeutics across all development phases.
Comprehensive Purity and Impurity Profiling
We employ a battery of orthogonal techniques to quantify product-related variants and process-related impurities. This includes high-resolution size exclusion chromatography (SEC-HPLC) for aggregation and fragmentation analysis, capillary electrophoresis (CE-SDS) under reducing and non-reducing conditions for size heterogeneity, reversed-phase HPLC (RP-HPLC) and hydrophobic interaction chromatography (HIC) for charge and hydrophobicity variants, and ion exchange chromatography (IEX) for charge variant profiling. Sensitive methods like host cell protein (HCP) ELISA and Residual DNA quantification are also employed toensure process impurity clearance. We also develop and validate specific assays for product-related impurities like oxidized species or deamidated variants.
Advanced Structural Characterization
Our structural characterization platform provides deep molecular insight across all levels of protein architecture. Intact mass analysis using high-resolution mass spectrometry (HRMS) confirms the primary structure, verifies molecular integrity, and sensitively detects major variants or modifications. Comprehensive peptide mapping by LC-MS/MS delivers residue-level sequence confirmation, while simultaneously identifying and localizing key post-translational modifications (PTMs) such as glycosylation, oxidation, and deamidation.
Functional Potency and Bioactivity Assessment
Establishing biological function is just as critical as defining structure. We develop and validate robust cell-based assays specifically designed around molecule's mechanism of action (MoA). These assays measure key functional endpoints, such as receptor engagement, neutralization capacity, cell proliferation, or cytotoxicity, to accurately reflect therapeutic activity.To complement cell-based methods, we employ high-precision binding analyses using surface plasmon resonance (SPR/Biacore) and bio-layer interferometry (BLI). These technologies provide detailed kinetic parameters (kon, koff) and equilibrium affinity (KD) for interactions with relevant targets. For enzymatic therapeutics, dedicated activity assays are established to quantify catalytic performance under controlled conditions.
Physicochemical Property Analysis
Understanding inherent properties is crucial for formulation development and stability. We perform dynamic light scattering (DLS) for hydrodynamic size and particle assessment, differential scanning calorimetry (DSC) to determine thermal stability and melting temperatures, circular dichroism (CD) for secondary structure evaluation, and analytical ultracentrifugation (AUC) for definitive solution molecular weight and complex formation analysis.
Stability and Comparability Studies
We design and execute forced degradation (stress) studies to identify degradation pathways and establish stability-indicating methods. Formal ICH-compliant stability studies under various storage conditions (real-time and accelerated) are conducted to support shelf-life determination. We also perform comprehensive analytical comparability assessments to bridge process changes, site transfers, or scale-up, ensuring product consistency.
Moreover, our scientists excel in developing fit-for-purpose analytical methods optimized for specific molecule and stage of development. We provide full GMP method validation per ICH Q2(R1)/Q14 guidelines, including specificity, accuracy, precision, linearity, range, detection/quantitation limits, and robustness. We expertly manage method transfer to client sites or other QC laboratories.
Partnering with us for your mammalian protein analytical needs means accessing unparalleled expertise, cutting-edge technologies, and a commitment to quality that underpins every stage of your biotherapeutic candidate's journey. Contact our analytical science team today to discuss how our tailored characterization strategies can empower your program's success.
Our products and services are for research use only.
